Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - budesonide - inhalation powder - 400microgram/1dose

Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - budesonide -

Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - budesonide -

Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - budesonide -

Stati Uniti - inglese - NLM (National Library of Medicine)

a-s medication solutions - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - pulmicort flexhaler is indicated for the maintenance treatment of asthma as prophylactic therapy in patients six years of age or older. limitations of use: •pulmicort flexhaler is not indicated for the relief of acute bronchospasm. the use of pulmicort flexhaler is contraindicated in the following conditions: risk summary there are no adequate well-controlled studies of pulmicort flexhaler in pregnant women. however, there are published studies on the use of budesonide, the active ingredient in pulmicort flexhaler, in pregnant women. in animal reproduction studies, budesonide, administered by the subcutaneous route, caused structural abnormalities, was embryocidal, and reduced fetal weights in rats and rabbits at less than the maximum recommended human daily inhalation dose (mrhdid), but these effects were not seen in rats that received inhaled doses approximately 2 times the mrhdid (see data ). studies of pregnant women have not shown that inhaled budesonide increases the risk of abnormalities when administe